Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-25-286168·Lyra Therapeutics, Inc.
Schedule 13D ownership disclosure
LYRA THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 55234L204
Event date: 2025-11-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLCReported CIK 0001224962
Shares: 98,301 · Class: 5.5%
- Joseph EdelmanReported CIK 0001164426
Shares: 98,301 · Class: 5.5%
- Perceptive Life Sciences Master Fund, Ltd.Reported CIK 0001249675
Shares: 88,374 · Class: 5.0%
- Perceptive LS (A), LLCReported CIK 0001797811
Shares: 9,927 · Class: 0.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-286168
- Form type
- SCHEDULE 13D/A
- Filer
- Lyra Therapeutics, Inc.
- CIK
- CIK 1327273
- Filed
- Nov 18, 2025
- Reporting period
- Nov 14, 2025
- Description
- Schedule 13D beneficial ownership